Cadrenal Therapeutics, Inc. Common Stock (CVKD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
822 A1A North
Ponte Vedra, FL 32082
United States of America (the)
Phone
904 300 0701
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
January 20, 2023
| Name | Title | Pay | Year Born |
| Quang X. Pham | Chairman, CEO, Interim CFO & Interim Principal Accounting Officer | 1.06M | 1965 |
| Jeffrey Cole | Chief Operating Officer | 615,361 | 1968 |
| James J. Ferguson FACC | Chief Medical Officer | 616,889 | 1954 |
| Matthew K. Szot | Co-Founder & Chief Financial Officer | 654,969 | 1974 |
| Matthew Boxer | Executive Vice President of Corporate Development | 0 | N/A |
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.